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Mosaic copy number variation in schizophrenia
Douglas M Ruderfer1,2,3, Kim Chambert1, Jennifer Moran1, Michael Talkowski4,5, Elizabeth S Chen6,
Carolina Gigek6, James F Gusella4,5, Douglas H Blackwood7, Aiden Corvin8, Hugh M Gurling9,
Christina M Hultman10,11, George Kirov12, Patrick Magnusson10, Michael C O’Donovan12, Michael J Owen12,
Carlos Pato13, David St Clair14, Patrick F Sullivan15, Shaun M Purcell1,2,3, Pamela Sklar2 and Carl Ernst*,6
Recent reports suggest that somatic structural changes occur in the human genome, but how these genomic alterations might
contribute to disease is unknown. Using samples collected as part of the International Schizophrenia Consortium
(schizophrenia, n¼3518; control, n¼4238) recruited across multiple university research centers, we assessed
single-nucleotide polymorphism genotyping arrays for evidence of chromosomal anomalies. Data from genotyping arrays on each
individual were processed using Birdsuite and analyzed with PLINK. We validated potential chromosomal anomalies using
custom nanostring probes and quantitative PCR. We estimate chromosomal alterations in the schizophrenia population to be
0.42%, which is not significantly different from controls (0.26%). We identified and validated a set of four extremely large
(410 Mb) chromosomal anomalies in subjects with schizophrenia, including a chromosome 8 trisomy and deletion of the q arm
of chromosome 7. These data demonstrate that chromosomal anomalies are present at low frequency in blood cells of both
control and schizophrenia subjects.
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INTRODUCTION
Schizophrenia (SCZ) is a highly heritable, debilitating psychiatric
disorder characterized by psychosis and cognitive deficits, and has a
lifetime prevalence of B0.5–0.7%.1,2 Recent studies into the genetic
architecture of this disease have implicated both common single-
nucleotide polymorphisms (SNPs) and rare copy number variants
(CNVs).3–5 In particular, recent studies of rare CNVs in SCZ have
identified both individuals with single events of high penetrance and
abundant events across the genome. Specifically, CNVs 4500 kb at
22q11–13, 15q11, 15q13, 3q29, 7q36.3 and 1q21 have been linked to
SCZ in B1% of cases.3,6–9 In addition, it has been shown that
individuals with SCZ are more likely to carry large, rare CNVs than
individuals without the disorder. This ‘burden’ has also been shown
to be significant in singleton CNVs – those CNVs observed only once
in a particular sample.
Recent reports suggest that somatic structural changes in the
nuclear genome are not uncommon and can be identified using
SNP genotyping arrays,10–12 at least when using DNA from white
blood cells. These studies have detected a mosaicism rate from 0.23 to
2% and mosaicism has been observed in 7 to 95% of lymphocytes
based on probe intensity measures. No disease study has yet revealed a
difference between cases and controls on this measure.
The purpose of this study was to determine differences between
SCZ cases and controls with respect to structural changes in the
genome of white blood cells, and how frequently these anomalies arise
in the SCZ population, within the limitation of the detection
resolution of SNP genotyping arrays. Our data suggest that both
control and SCZ populations carry large chromosomal anomalies in
blood cells at frequencies under 0.5%.
MATERIALS AND METHODS
Samples
Samples used in this study have been described previously and quality control
measures have been thoroughly detailed.3,13 Subjects in this study passed all
QC measures for chip quality as with our previous analysis.3 Individuals were
placed into nine groups based on site, collection date and/or Affymetrix array
used (Table 1). All DNA used in the original International Schizophrenia
Consortium (ISC) study or for validation in this study was derived from whole
blood. Independently, we also used samples from the Molecular Genetics of
Schizophrenia Genetic Association Information Network (GAIN) as an
external validation set, with the caveat that increased rates of abnormality
might be observed because these DNA samples were derived from Epstein–
Barr virus-transformed lymphocytes. Samples were genotyped by the Genetic
Analysis Platform at The Broad Institute of Harvard and MIT according to
standard protocols as described previously.3 Both the Affymetrix 5.0 and 6.0
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arrays were used (Table 1) and CNVs were identified using Birdseye,14 which
identifies rare CNVs by integrating intensity data from neighboring probes
using a hidden Markov model (HMM) on a per-individual basis. Performance
is dependent on a number of factors including SNP and copy number probe
density, and mean intraindividual probe variance. Covariate analysis was
carried out to control for 96-well plate effects. For each copy number change,
an LOD score was generated that describes the likelihood of the copy change
relative to no copy change over the given interval. Large copy number
changes were assessed after removing CNVs o20 kb or with LOD scores o10
and after joining segments appearing to be incorrectly split by the HMM. Rare
CNVs were defined as being seen in o1% of the sample following the same
procedure described previously3 in PLINK.15
We were particularly interested in subjects with a large extent of CNVs and/
or those subjects with many CNVs, as both of these situations could reveal
subjects with large CNVs (ie, chromosomal CNVs, or very large duplications/
deletions). ‘Large extent of CNV’ refers to the situation where a single large
CNV is identified, while ‘many CNVs’ refer to a situation where a single subject
has an abnormally high level of CNVs, far from the group mean.
Nanostring analysis
One to four probes were designed to regions of interest by Nanostring
Technologies (http://www.nanostring.com/). An oligonucleotide reporter
probe was synthesized to each region ligated to one of six fluorophores
ligated. A separate capture probe, which pairs with the reporter probe:DNA
hybrid, then allows the complex to attach to a matrix for imaging. No
amplification steps are required for this reaction. After hybridization, samples
were transferred to the nCounter Prep Station where excess probes were
removed and probe/target complexes were aligned and immobilized in the
nCounter Cartridge. Cartridges were then placed in the nCounterDigital
Analyzer for imaging. To control for the amount of DNA present across all
samples, a spike-in plasmid was used and served as a positive control. Further,
optimized probe pairs for 10 invariant regions of the genome were included for
data normalization. Other controls were used to ensure optimal hybridization
and purification efficiency.
Quantitative polymerase chain reaction
Once CNVs were identified, we randomly selected subregions from CNVs that
did not overlap with subregions validated by nanostring. All primers were
designed in Primer3 (http://www.primer3.com/) and all amplification products
were between 100 and 180 basepairs. Using a LightCycler 480 II (Roche
Diagnostics, Basel, Switzerland) and SYBR green (Promega, Madison, WI,
USA), we assessed fluorescent signal over cycle time. At least two replicates
were used per region and a non-varying genomic region was assessed to
control for DNA concentration. All melting curves showed single peaks,
suggesting that primers bound efficiently and specifically. The second
derivative of the cycle threshold (Ct) was used for data analysis on factory-
loaded settings. For comparison, six control CEPH subjects from the HapMap
project were assessed.
RESULTS
We used SNP microarray data from 3518 SCZ patients and 4238
controls3 from nine sites (Table 1) to detect potentially large
chromosomal changes. Among the individuals from the complete
ISC sample set,3 the median number of rare copy number changes
4100 kb per individual is 1 (mean 0.9) and the median extent of
CNV is 129 kb (mean 267 kb). From this set, we identified 60 outliers
(defined as outside of 3 SDs from the mean extent of CNV) where the
median number of rare CNVs over 100 kb per outlier individual is 3
(mean¼ 9.7) and the median extent of CNV is 6.4 Mb (mean 17 Mb).
Figures 1 and 2 show the size and distribution of rare CNVs from
cases and controls in the outlier sample and Table 2 shows specific
subject information.
We defined an outlier sample set (cases and controls, n¼ 60) from
the initial ISC sample set (case and controls, n¼ 7756). In all, 36
outliers of 3518 cases were identified, whereas only 24 outliers of 4238
controls were identified (Fisher’s exact test P¼ 0.026; OR¼ 1.82). To
further address whether this outlier population was enriched for
individuals with SCZ, we performed logistic regression on phenotype
and outlier status, accounting for the nine sites, and array type
(Table 1) and gender as covariates. Overall, we found a significant
over-representation of SCZ cases compared with controls (P¼ 0.019),
in line with our previous findings that suggest increased CNV burden
in people with SCZ.
No cell lines were used in the above analysis and all DNA processed
was isolated from blood. We had access to CNV data from the
Molecular Genetics of Schizophrenia GAIN, where there were 1324
controls and 1096 SCZ cases, with the caveat that most DNA was
isolated from lymphoblastoid cell lines.5 In this independent sample
set, we again observed enrichment in SCZ relative to control. Using
our previous criteria, we identified 22 case outliers and 12 control
outliers (GAIN sample only; Fisher’s exact text P¼ 0.024).
A number of copy number changes from this first analysis
represent scattered copy changes across the genome and thus are of
unclear quality and biological importance, despite passing array QC
parameters. To define only those subjects with potential chromosomal
anomalies (GAIN subjects are excluded from this analysis because of
potential confounds from cell line artifacts), we selected subjects with
very high extent of CNV (ie, suggesting a single large CNV). Of 36
cases, 15 were included in the outlier pool based on the extent of
CNV in the genome, whereas 11 of 24 controls did. Four schizo-
phrenic subjects and two wild-type subjects met the criteria for both
large CNVs and many CNVs. In all, 19 cases and 13 controls were
included in the outlier sample for having many CNVs. Thus, 0.42% of
the total sample of cases and 0.26% of controls had large structural
Table 1 Number of outlier subjects by site, genotyping platform and disease status
Sample Ancestry Genotyping platform Outlier controls Outlier SCZ All controls All SCZ
Cardiff University Bulgarian 6.0 3 3 561 406
Trinity College Dublin Irish 6.0 7 6 816 260
Portuguese Island Portuguese 5.0 1 7 182 293
University of Aberdeen Scottish 5.0 2 2 665 692
University of Edinburgh Scottish 6.0 1 7 279 357
Karolinska Institutet 1 Swedish 5.0 1 0 138 144
Karolinska Institutet 2 Swedish 6.0 4 7 227 369
Karolinska Institutet 3 Swedish 6.0 5 2 902 534
Unversity College London British 5.0 0 2 468 463
Total 24 36 4238 3518
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variation as assessed by SNP array, a number too small to detect a
statistically significant difference.
To give an example of the large variation observed, we present in
Table 3 nine cases and six controls with CNVs 410 Mb (the
minimum size of structural variation required for karyotype analysis,
under good conditions), of which one case carried two CNVs of this
size. Eight of these large CNVs included a putative duplication over
centromere 1 or centromere 9, and thus are of unknown validity given
the lack of probes in centromeric regions (consistent signal is detected
on either side of the centromere). In the GAIN sample, two cases and
one control had a single CNV 410 Mb.
We sought to confirm the existence of large chromosomal
anomalies, and accurate calling of structural variation from arrays,
by sampling DNA from some subjects. Using two different technol-
ogies, we chose two large duplications and two large deletions from
three independent cases (Figure 3). First, we used a series of custom
nanostring probes to assess whether an increased or decreased signal
corresponded with the genomic location of the CNV call from the
arrays. As these were large events, we used multiple probes targeting
different regions of the CNV (Figure 3). In each case, we were able to
validate the array data for the existence of the event and an estimate
of size (probes were placed across chromosome but did not cover the
entirety of the called event). Second, we performed quantitative PCR
on each large CNV from these subjects (Table 4). Data generated from
all three technologies were in agreement (Table 4).
DISCUSSION
We used SNP genotyping arrays to call copy number gains and losses
in the genome, and identified a structural variant rate of approxi-
mately 0.42% in blood cells from people with SCZ. This was a large
study with close to 8000 subjects, but we could not detect a significant







1 Cardiff University Case 44 10 452
2 Cardiff University Case 35 7818.9
3 Cardiff University Case 7 1534.5
4 Cardiff University Control 2 5894.6
5 Cardiff University Control 3 117.4
6 Cardiff University Control 1 2734.4
7 Karolinska Institutet 1 Control 2 7818.4
8 Karolinska Institutet 2 Case 6 22 471.4
9 Karolinska Institutet 2 Case 70 18 293.5
10 Karolinska Institutet 2 Control 5 574
11 Karolinska Institutet 2 Case 3 146246
12 Karolinska Institutet 2 Case 44 8286.6
13 Karolinska Institutet 2 Case 6 140142
14 Karolinska Institutet 2 Control 4 574
15 Karolinska Institutet 2 Control 6 810.7
16 Karolinska Institutet 2 Control 3 4713.7
17 Karolinska Institutet 2 Case 17 2645.1
18 Karolinska Institutet 2 Case 235 88 960.6
19 Karolinska Institutet 3 Control 4 22 003.3
20 Karolinska Institutet 3 Control 1 20 395.1
21 Karolinska Institutet 3 Control 4 3077.3
22 Karolinska Institutet 3 Case 6 7647.7
23 Karolinska Institutet 3 Control 22 1778.6
24 Karolinska Institutet 3 Control 11 200119
25 Karolinska Institutet 3 Case 3 217.5
26 Portuguese Island Collection Case 170 71 472.4
27 Portuguese Island Collection Case 7 12 308
28 Portuguese Island Collection Case 28 6258.8
29 Portuguese Island Collection Case 70 12 505.7
30 Portuguese Island Collection Case 23 13 736.5
31 Portuguese Island Collection Control 3 13 789.8
32 Portuguese Island Collection Case 36 18 127.9
33 Portuguese Island Collection Case 29 7752.9
34 Trinity College Dublin Case 32 3654.3
35 Trinity College Dublin Case 3 1500.5
36 Trinity College Dublin Case 4 22 544.7
37 Trinity College Dublin Case 4 3683.9
38 Trinity College Dublin Case 1 35.3
39 Trinity College Dublin Case 4 19 874
40 Trinity College Dublin Control 58 11 300
41 Trinity College Dublin Control 1 2872.8
42 Trinity College Dublin Control 37 4086.7
43 Trinity College Dublin Control 492 484548
44 Trinity College Dublin Control 341 126722
45 Trinity College Dublin Control 199 43 711.3
46 Trinity College Dublin Control 234 142143
47 University College London Case 1 39.7
48 University College London Case 178 52 199.9
49 University of Aberdeen Case 2 291.8
50 University of Aberdeen Control 3 13 181.8
51 University of Aberdeen Case 122 54 641.3
52 University of Aberdeen Control 1111 232645
53 University of Edinburgh Control 53 28 277.4
54 University of Edinburgh Case 26 2890.2
55 University of Edinburgh Case 9 7167.6
56 University of Edinburgh Case 7 4178.9
57 University of Edinburgh Case 66 14 659.6
58 University of Edinburgh Case 10 3985.3
59 University of Edinburgh Case 21 1978.2
60 University of Edinburgh Case 659 283661
Figure 1 Distribution of number of rare CNVs and total extent of rare CNV
by individual. Red dots represent cases and black dots represent controls. A
full color version of this figure is available at the European Journal of
Human Genetics journal online.
Figure 2 Size and number of CNVs in the outlier sample.
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difference in the rate of chromosomal anomalies in cases compared
with controls, where the rate of structural variation in controls was
0.23%. All CNVs described here are ‘chromosomal’ in nature, ranging
from 10 Mb to complete chromosomal copy number changes. Many
of these changes are not viable with life and thus subjects carrying
these alterations are mosaic – that is, some cells in different tissues
have post-zygotic mutations not shared by all cells from the
individual.
Similar studies using SNP arrays to call large structural variation
identified have similar rates of aberrations. For example, in the study
by Jacobs et al,12 the rate of mosaicism in 26 136 controls was
identical to our study (0.23%). In contrast, mosaicism in a bladder
cancer study of 1991 individuals (957 controls) was 1.7%.11 Increased
rate of mosaicism is frequently observed in cancer cells, which is likely
the driver of this difference. We detected almost a twofold increase in
large deletion/duplication variation in the SCZ population, suggesting
that with greater power, significant differences between groups might
arise. Still, it seems unlikely that such large structural variation
(eg, trisomy on chromosome 8) has an affect on SCZ, nor is it clear
how post-zygotic changes in non-neural tissue might influence
disease.
Analysis of DNA extracted from brain rather than lymphocytes
could have revealed different results. It is not clear, for example, what
the relationship is between lymphocyte mosaicism and neuron
mosaicism. It may be that rates in (postmitotic) neurons are very
low compared with lymphocytes that continuously renew, providing
more opportunities for genomic alterations over time in blood cells.
While brain DNA would likely be more relevant to psychiatric disease,
it is also much harder to acquire, being restricted to DNA extraction
from brains stored in brain banks. The benefit of using lymphocytes is
the large number of subjects that can be sampled, which is crucial
given the small number of mosaic events detected. Two studies have
looked at CNV events using brain DNA,16,17 the former with a sample
size of 600 and the latter using 35 brains. Neither study assessed
mosaicsm, and each found only single sites of potential pathology.
Still, these studies document the benefits of studying CNV events
using DNA from human brain.
In this study, a majority of subjects met the criteria because of
many CNVs, rather than a single large CNV. While this was a function
of the filtering paradigm to find large structural variations and these
subjects were removed from further analysis in this study – they did
not have large structural variation – they may reflect legitimate
findings and not technical artifacts. This follows with our previous
finding of increased burden of CNVs in the genome; however,
the sheer number of scattered CNVs across the genome of some
individuals is suspiciously high, but may warrant further analysis.
Mosaicism rates are likely higher for both cases and controls than
that reported here. First, we only used stringent array filtering criteria,
which revealed only subjects with a large majority of cells carrying the
same genotype. Specifically, mosaicism can be described in terms of
percent mosaicism, that is, what proportion of cells from a given
tissue are mosaic. In the quantitative PCR and nanostring validation
component of our study, we observed ratios of approximately 3:2 for
duplications and 2:1 for deletions, strongly suggesting that all
lymphocytes carry the mutation. Thus, any subjects mosaic for, for
example, 50% of cells would not have been detected. Second, our
study design could only detect specific types of chromosomal
alterations; we were unable to detect balanced chromosomal translo-
cations, for example, suggesting that the true rate of chromosomal
aberrations is in actuality much higher.
Figure 3 Non-centromeric CNVs 410 Mb identified in a refined set of
outlier subjects. Red squares indicate where on the chromosome the loss
(del) or gain (dup) occurred. Regions of quantitative PCR (qPCR) and
nanostring probe binding are marked by small squares adjacent to
chromosome images. A full color version of this figure is available at the
European Journal of Human Genetics journal online.
Table 3 Case and control subjects with CNVs 410 Mb (CEN denotes
CNV overlaps centromere)
ID Phenotype Position (Hg18)
1 Control Chr3: 1–199 501 827
2 Control Chr4: 177 461 444–191 032 806
3 Control Chr18: 81 453–11557 558
4 Case Chr4: 60 028 470–70412 078
5 Case Chr8: 1–146 274 826
6 Case Chr7: 61512 866–158 819 766
6 Case Chr1: 143 543 613–247 191 012
7 Case Chr5: 92668 239–120 870 769
8 Control CEN chr9: 45929 611–66 324 680
9 Control CEN chr1: 120 549 231–142 770 366
10 Control CEN chr9: 41682 298–69 122 542
11 Case CEN chr9: 45258 767–68 352 799
12 Case CEN chr1: 120 549 231–142 770 366
13 Case CEN chr9: 45003 665–69 134 634
14 Case CEN chr9: 45332 198–66 219 272
15 Case CEN chr1: 120 549 231–142 770 366










1 1 2 2.77±0.060 1.52
Trinity College
Dublin
2 5 1 1.1 2.04
Karolinska
Institutet 2
1 7 7 1.06±0.35 1.96
Karolinska
Institutet 2
3 8 10 2.35±0.030 1.55
Abbreviations: ID, individual; CHR, chromosome number; qPCR, quantitative PCR.
Numbers in the nanostring column represent copy number changes compared with controls
normalized by control gene regions (2.0¼ no loss or gain). Numbers in the qPCR column
represent fold change difference of a single case subject compared with CEPH controls (n¼6),
normalized to a gene region.
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This study suggests that the frequency of mosaic structural
variation in blood cells from people with SCZ is B0.42%, almost
double that observed in control subjects. Still, overall numbers were
too small to detect a difference between cases and controls. Future
studies might assess multiple tissues for mosaicism from people with
SCZ, use different technology to assess copy changes across tissues,
increase sample sizes and better study those subjects with multiple
small CNVs throughout their genomes.
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